{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:26:03Z","timestamp":1791429963002,"version":"4.3.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 CA227763"],"award-info":[{"award-number":["R01 CA227763"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["A81XWH-18-1-0671"],"award-info":[{"award-number":["A81XWH-18-1-0671"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCSF Department of Surgery"},{"name":"National Cancer Institute","award":["K08CA256047"],"award-info":[{"award-number":["K08CA256047"]}]},{"name":"American Cancer Society Individual Research Grant"},{"name":"UCSF Resource Allocation Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Invasive lobular carcinoma (ILC) of the breast presents challenges in monitoring response to neoadjuvant endocrine therapy (NET). Dedicated breast positron emission tomography with\n                      <jats:sup>18<\/jats:sup>\n                      F-fluoroestradiol (FES-dbPET), a molecular imaging technique targeting the estrogen receptor (ER), may offer insight into treatment response. This study evaluated whether changes in FES-dbPET uptake before and after NET in patients with ILC correlate with treatment response indicators, and whether these associations differ by endocrine therapy type.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective pilot study included patients with stage I-III ER positive, human epidermal growth factor 2 (HER2) negative ILC undergoing NET between 2017 and 2021. FES-dbPET was performed pre- and post-NET. Patients were stratified by type of NET received \u2013 aromatase inhibitor (AI) therapy or selective estrogen receptor modulator\/degrader (SERM\/SERD) therapy. The primary goal was to assess correlation between FES-dbPET parameters and change in tumor Ki-67 staining (%), a validated prognostic endpoint after NET.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We enrolled 19 patients with ER\u2009+\u2009HER2- ILC, of whom 12 underwent both pre- and post-NET FES-dbPET. Among the AI cohort, changes in SUVpk and SULpk from pre- to post-NET each positively correlated with changes in Ki-67, though these associations did not reach statistical significance (r\u2009=\u20090.74,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.256; and r\u2009=\u20090.75,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.254, respectively). Conversely, among the SERM\/SERD cohort, changes in SUVpk and SULpk strongly and positively correlated with changes in Ki-67 (r\u2009=\u20090.92,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027; and r\u2009=\u20090.92,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this pilot study of 19 ER\u2009+\u2009ILC patients, change in FES uptake on dbPET showed some correlations with tumor response to NET. These findings suggest potential for FES-dbPET to capture tumor biology beyond that of standard imaging tools in predicting therapy response for patients with ILC. Further research with larger samples is needed to refine the role of FES-dbPET in improving neoadjuvant treatment monitoring and surgical planning in ILC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02277-w","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:55:09Z","timestamp":1775886909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy"],"prefix":"10.1186","volume":"28","author":[{"given":"Kayla M.","family":"Switalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella F.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Lawhn-Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly M.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deep K.","family":"Hathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Carmona-Bozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Metanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel O.","family":"Falade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Quirarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Gottipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julissa","family":"Molina-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Pullakhandam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teffany Joy","family":"Bareng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jo","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie N.","family":"Joe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nola","family":"Hylton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"2277_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182397","volume":"12","author":"Z Chen","year":"2017","unstructured":"Chen Z, et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS ONE. 2017;12:e0182397. https:\/\/doi.org\/10.1371\/journal.pone.0182397.","journal-title":"PLoS ONE"},{"key":"2277_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.soc.2017.07.005","volume":"27","author":"A Mamtani","year":"2018","unstructured":"Mamtani A, King TA. Lobular breast cancer: different disease, different algorithms? Surg Oncol Clin N Am. 2018;27:81\u201394. https:\/\/doi.org\/10.1016\/j.soc.2017.07.005.","journal-title":"Surg Oncol Clin N Am"},{"key":"2277_CR3","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-022-06572-w","volume":"193","author":"JA Mouabbi","year":"2022","unstructured":"Mouabbi JA, et al. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022;193:253\u201364. https:\/\/doi.org\/10.1007\/s10549-022-06572-w.","journal-title":"Breast Cancer Res Treat"},{"key":"2277_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00627-5","volume":"10","author":"K Van Baelen","year":"2024","unstructured":"Van Baelen K, et al. Reporting on invasive lobular breast cancer in clinical trials: a systematic review. NPJ Breast Cancer. 2024;10:23. https:\/\/doi.org\/10.1038\/s41523-024-00627-5.","journal-title":"NPJ Breast Cancer"},{"key":"2277_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1148\/radiol.2333031484","volume":"233","author":"WA Berg","year":"2004","unstructured":"Berg WA, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233:830\u201349. https:\/\/doi.org\/10.1148\/radiol.2333031484.","journal-title":"Radiology"},{"key":"2277_CR6","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/bcr767","volume":"6","author":"G Arpino","year":"2004","unstructured":"Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149-156. https:\/\/doi.org\/10.1186\/bcr767.","journal-title":"Breast Cancer Res"},{"key":"2277_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0605-0","volume":"17","author":"K Johnson","year":"2015","unstructured":"Johnson K, Sarma D, Hwang ES. Lobular breast cancer series: imaging. Breast Cancer Res. 2015;17:94. https:\/\/doi.org\/10.1186\/s13058-015-0605-0.","journal-title":"Breast Cancer Res"},{"key":"2277_CR8","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1245\/s10434-010-0953-z","volume":"17","author":"N Wasif","year":"2010","unstructured":"Wasif N, Maggard MA, Ko CY, Giuliano AE. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol. 2010;17:1862\u20139. https:\/\/doi.org\/10.1245\/s10434-010-0953-z.","journal-title":"Ann Surg Oncol"},{"key":"2277_CR9","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1245\/s10434-018-6682-4","volume":"25","author":"RA Mukhtar","year":"2018","unstructured":"Mukhtar RA, et al. Breast conservation and negative margins in invasive lobular carcinoma: the impact of oncoplastic surgery and shave margins in 358 patients. Ann Surg Oncol. 2018;25:3165\u201370. https:\/\/doi.org\/10.1245\/s10434-018-6682-4.","journal-title":"Ann Surg Oncol"},{"key":"2277_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00508-023-02162-y","volume":"135","author":"S Danzinger","year":"2023","unstructured":"Danzinger S, et al. Axillary lymph node status and invasive lobular breast cancer\u202f: analysis of the clinical tumor register of the AGO Austria. Wien Klin Wochenschr. 2023;135:463\u201371. https:\/\/doi.org\/10.1007\/s00508-023-02162-y.","journal-title":"Wien Klin Wochenschr"},{"key":"2277_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s10549-017-4324-3","volume":"165","author":"N Houssami","year":"2017","unstructured":"Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat. 2017;165:273\u201383. https:\/\/doi.org\/10.1007\/s10549-017-4324-3.","journal-title":"Breast Cancer Res Treat"},{"key":"2277_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00366-x","volume":"7","author":"MK Abel","year":"2021","unstructured":"Abel MK, et al. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database study. NPJ Breast Cancer. 2021;7:156. https:\/\/doi.org\/10.1038\/s41523-021-00366-x.","journal-title":"NPJ Breast Cancer"},{"key":"2277_CR13","doi-asserted-by":"publisher","first-page":"7212","DOI":"10.1200\/jco.2005.07.501","volume":"23","author":"A Urruticoechea","year":"2005","unstructured":"Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212\u201320. https:\/\/doi.org\/10.1200\/jco.2005.07.501.","journal-title":"J Clin Oncol"},{"key":"2277_CR14","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"M Dowsett","year":"2011","unstructured":"Dowsett M, et al. Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2011;103:1656\u201364. https:\/\/doi.org\/10.1093\/jnci\/djr393.","journal-title":"J Natl Cancer Inst"},{"key":"2277_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10549-017-4329-y","volume":"165","author":"R Goncalves","year":"2017","unstructured":"Goncalves R, et al. Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat. 2017;165:355\u201364. https:\/\/doi.org\/10.1007\/s10549-017-4329-y.","journal-title":"Breast Cancer Res Treat"},{"key":"2277_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/s1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith I, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 2020;21:1443\u201354. https:\/\/doi.org\/10.1016\/s1470-2045(20)30458-7.","journal-title":"Lancet Oncol"},{"key":"2277_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10549-017-4421-3","volume":"166","author":"MA Healey","year":"2017","unstructured":"Healey MA, et al. Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the nurses\u2019 health study. Breast Cancer Res Treat. 2017;166:613\u201322. https:\/\/doi.org\/10.1007\/s10549-017-4421-3.","journal-title":"Breast Cancer Res Treat"},{"key":"2277_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113:808\u201319. https:\/\/doi.org\/10.1093\/jnci\/djaa201.","journal-title":"J Natl Cancer Inst"},{"key":"2277_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.905575","volume":"9","author":"S Li","year":"2022","unstructured":"Li S, Chen X, Shen K. Association of Ki-67 change pattern after core needle biopsy and prognosis in HR+\/HER2- early breast cancer patients. Front Surg. 2022;9:905575. https:\/\/doi.org\/10.3389\/fsurg.2022.905575.","journal-title":"Front Surg"},{"key":"2277_CR20","doi-asserted-by":"publisher","first-page":"e465","DOI":"10.1016\/s1470-2045(13)70292-4","volume":"14","author":"M van Kruchten","year":"2013","unstructured":"van Kruchten M, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013;14:e465\u201375. https:\/\/doi.org\/10.1016\/s1470-2045(13)70292-4.","journal-title":"Lancet Oncol"},{"key":"2277_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.soc.2022.06.001","volume":"31","author":"K Goodman","year":"2022","unstructured":"Goodman K, et al. molecular imaging for estrogen receptor-positive breast cancer: clinical applications of whole body and dedicated breast positron emission tomography. Surg Oncol Clin N Am. 2022;31:569\u201379. https:\/\/doi.org\/10.1016\/j.soc.2022.06.001.","journal-title":"Surg Oncol Clin N Am"},{"key":"2277_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78865-3","volume":"10","author":"DK Hathi","year":"2020","unstructured":"Hathi DK, et al. Evaluation of primary breast cancers using dedicated breast PET and whole-body PET. Sci Rep. 2020;10:21930. https:\/\/doi.org\/10.1038\/s41598-020-78865-3.","journal-title":"Sci Rep"},{"key":"2277_CR23","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.241850","volume":"314","author":"JJ Knip","year":"2025","unstructured":"Knip JJ, et al. The diagnostic accuracy of (18)F-FDG PET and (18)F-FES PET for staging Grade 1-2 estrogen receptor-positive breast cancer. Radiology. 2025;314:e241850. https:\/\/doi.org\/10.1148\/radiol.241850.","journal-title":"Radiology"},{"key":"2277_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10549-023-07059-y","volume":"202","author":"EN Clelland","year":"2023","unstructured":"Clelland EN, et al. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes. Breast Cancer Res Treat. 2023;202:367\u201375. https:\/\/doi.org\/10.1007\/s10549-023-07059-y.","journal-title":"Breast Cancer Res Treat"},{"key":"2277_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.prp.2016.05.002","volume":"212","author":"M Christgen","year":"2016","unstructured":"Christgen M, et al. Lobular breast cancer: clinical, molecular and morphological characteristics. Pathol Res Pract. 2016;212:583\u201397. https:\/\/doi.org\/10.1016\/j.prp.2016.05.002.","journal-title":"Pathol Res Pract"},{"key":"2277_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2967\/jnumed.123.265420","volume":"64","author":"GA Ulaner","year":"2023","unstructured":"Ulaner GA, et al. Summary: appropriate use criteria for estrogen receptor-targeted PET imaging with 16\u03b1-(18)F-Fluoro-17\u03b2-Fluoroestradiol. J Nucl Med. 2023;64:351\u20134. https:\/\/doi.org\/10.2967\/jnumed.123.265420.","journal-title":"J Nucl Med"},{"key":"2277_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.annonc.2024.02.007","volume":"35","author":"A Gennari","year":"2024","unstructured":"Gennari A, et al. Early prediction of endocrine responsiveness in ER+\/HER2-negative metastatic breast cancer (MBC): pilot study with (18)F-fluoroestradiol ((18)F-FES) CT\/PET. Ann Oncol. 2024;35:549\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.007.","journal-title":"Ann Oncol"},{"key":"2277_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0093-7754(03)00302-6","volume":"30","author":"WR Miller","year":"2003","unstructured":"Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol. 2003;30:3\u201311. https:\/\/doi.org\/10.1016\/s0093-7754(03)00302-6.","journal-title":"Semin Oncol"},{"key":"2277_CR29","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2174\/092986710790820633","volume":"17","author":"SJ Johnston","year":"2010","unstructured":"Johnston SJ, Cheung KL. Fulvestrant\u2013a novel endocrine therapy for breast cancer. Curr Med Chem. 2010;17:902\u201314. https:\/\/doi.org\/10.2174\/092986710790820633.","journal-title":"Curr Med Chem"},{"key":"2277_CR30","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1158\/1078-0432.Ccr-06-1136","volume":"12","author":"VC Jordan","year":"2006","unstructured":"Jordan VC. The science of selective estrogen receptor modulators: concept to clinical practice. Clin Cancer Res. 2006;12:5010\u20133. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-1136.","journal-title":"Clin Cancer Res"},{"key":"2277_CR31","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.116.178368","volume":"58","author":"SY Chae","year":"2017","unstructured":"Chae SY, et al. A randomized feasibility study of (18)F-Fluoroestradiol PET to predict pathologic response to neoadjuvant therapy in estrogen receptor-rich postmenopausal breast cancer. J Nucl Med. 2017;58:563\u20138. https:\/\/doi.org\/10.2967\/jnumed.116.178368.","journal-title":"J Nucl Med"},{"key":"2277_CR32","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00280-016-3107-6","volume":"78","author":"JH Park","year":"2016","unstructured":"Park JH, et al. Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers. Cancer Chemother Pharmacol. 2016;78:685\u201395. https:\/\/doi.org\/10.1007\/s00280-016-3107-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2277_CR33","doi-asserted-by":"publisher","unstructured":"Chien AJ, K. K., Molina-Vega J, Mukhtar R, Giridhar K, Olopade OI, Basu A, Asare SM, Henderson P, Hirst G, Lu R, Jones E, Hylton N, Brown-Swigart L, van\u2019t Veer LJ, Yee D, Mayer I, Esserman LJ. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+\/HER2- clinical stage 2\/3 breast cancer. San Antonio Breast Cancer Symposium (2021).https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-OT1-10-02","DOI":"10.1158\/1538-7445.SABCS21-OT1-10-02"},{"key":"2277_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-019-0107-9","volume":"5","author":"EF Jones","year":"2019","unstructured":"Jones EF, et al. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019;5:12. https:\/\/doi.org\/10.1038\/s41523-019-0107-9.","journal-title":"NPJ Breast Cancer"},{"key":"2277_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1634\/theoncologist.2011-0121","volume":"16","author":"G Braems","year":"2011","unstructured":"Braems G, Denys H, De Wever O, Cocquyt V, Van den Broecke R. Use of tamoxifen before and during pregnancy. Oncologist. 2011;16:1547\u201351. https:\/\/doi.org\/10.1634\/theoncologist.2011-0121.","journal-title":"Oncologist"},{"key":"2277_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12060867","author":"M Costantini","year":"2022","unstructured":"Costantini M, et al. Diagnostic challenge of invasive lobular carcinoma of the breast: what is the news? Breast magnetic resonance imaging and emerging role of contrast-enhanced spectral mammography. Journal of Personalized Medicine. 2022. https:\/\/doi.org\/10.3390\/jpm12060867.","journal-title":"Journal of Personalized Medicine"},{"key":"2277_CR37","first-page":"1766","volume":"36","author":"F Dehdashti","year":"1995","unstructured":"Dehdashti F, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766\u201374.","journal-title":"J Nucl Med"},{"key":"2277_CR38","first-page":"601","volume":"60","author":"E Jones","year":"2019","unstructured":"Jones E, et al. Dedicated breast PET for detection of early treatment response in breast cancer patients. J Nucl Med. 2019;60:601\u2013601.","journal-title":"J Nucl Med"},{"key":"2277_CR39","doi-asserted-by":"publisher","first-page":"692","DOI":"10.2967\/jnumed.124.269163","volume":"66","author":"AS Parihar","year":"2025","unstructured":"Parihar AS, et al. (18)F-Fluoroestradiol PET\/CT for predicting benefit from endocrine therapy in patients with estrogen receptor-positive breast cancer: a systematic review and metaanalysis. J Nucl Med. 2025;66:692\u20139. https:\/\/doi.org\/10.2967\/jnumed.124.269163.","journal-title":"J Nucl Med"},{"key":"2277_CR40","doi-asserted-by":"publisher","first-page":"4799","DOI":"10.1158\/1078-0432.Ccr-10-3321","volume":"17","author":"HM Linden","year":"2011","unstructured":"Linden HM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011;17:4799\u2013805. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-3321.","journal-title":"Clin Cancer Res"},{"key":"2277_CR41","doi-asserted-by":"publisher","first-page":"11075","DOI":"10.1200\/jco.2009.27.15_suppl.11075","volume":"27","author":"HM Linden","year":"2009","unstructured":"Linden HM, et al. Early assessment of response to aromatase inhibitor (AI) therapy. J Clin Oncol. 2009;27:11075\u201311075. https:\/\/doi.org\/10.1200\/jco.2009.27.15_suppl.11075.","journal-title":"J Clin Oncol"},{"key":"2277_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1148\/rg.2021200134","volume":"41","author":"B Reig","year":"2021","unstructured":"Reig B, et al. Breast MRI for evaluation of response to neoadjuvant therapy. Radiographics. 2021;41:665\u201379. https:\/\/doi.org\/10.1148\/rg.2021200134.","journal-title":"Radiographics"},{"key":"2277_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00720-3","volume":"11","author":"RA Mukhtar","year":"2025","unstructured":"Mukhtar RA, et al. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer. npj Breast Cancer. 2025;11:14. https:\/\/doi.org\/10.1038\/s41523-025-00720-3.","journal-title":"npj Breast Cancer"},{"key":"2277_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2967\/jnumed.120.247882","volume":"62","author":"GA Ulaner","year":"2021","unstructured":"Ulaner GA, et al. Head-to-head evaluation of (18)F-FES and (18)F-FDG PET\/CT in metastatic invasive lobular breast cancer. J Nucl Med. 2021;62:326\u201331. https:\/\/doi.org\/10.2967\/jnumed.120.247882.","journal-title":"J Nucl Med"},{"key":"2277_CR45","first-page":"341","volume":"8","author":"I Soldevilla-Gallardo","year":"2018","unstructured":"Soldevilla-Gallardo I, et al. Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer. Am J Nucl Med Mol Imaging. 2018;8:341\u201350.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"2277_CR46","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/jco-24-02263","volume":"43","author":"GM Choong","year":"2025","unstructured":"Choong GM, Hoskin TL, Boughey JC, Ingle JN, Goetz MP. Endocrine therapy omission in estrogen receptor-low (1\u201310%) early-stage breast cancer. J Clin Oncol. 2025;43:1875\u201385. https:\/\/doi.org\/10.1200\/jco-24-02263.","journal-title":"J Clin Oncol"},{"key":"2277_CR47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","volume":"11","author":"H Wang","year":"2019","unstructured":"Wang H, Yee D. I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer. Curr Breast Cancer Rep. 2019;11:303\u201310. https:\/\/doi.org\/10.1007\/s12609-019-00334-2.","journal-title":"Curr Breast Cancer Rep"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02277-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02277-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:49:15Z","timestamp":1781646555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02277-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2277"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02277-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the UCSF Institutional Review Board (IRB# 16-19959).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"KMS. No relevant relationships. NO. No relevant relationships. EFJ. This work was prepared while EFJ was employed at UCSF. The opinions expressed in this article are the author\u2019s own and do not reflect the view of the National Institutes of Health, the Department of Health and Human Services, or the United States government. CLH. No relevant relationships. KMR. No relevant relationships. DKH. Employed by and owns stock in Regeneron Pharmaceuticals. JCB. No relevant relationships. PM. No relevant relationships. AJL. No relevant relationships. IOF. No relevant relationships. AQ. No relevant relationships. SG. No relevant relationships. RG. No relevant relationships. JMV. No relevant relationships. KP. No relevant relationships. TJB. No relevant relationships. MW. No relevant relationships. AJC. No relevant relationships. BNJ. Author royalties from UpToDate; research grant from Kheiron Medical Technologies, Ltd; honoraria for lectures from the American College of Radiology, World Class CME, and Medscape; travel reimbursement for attending meetings from RSNA, American College of Radiology, National Diagnostic Imaging Symposium, and Medscape; member of the board of trustees of the RSNA Research and Education Foundation; deputy editor for Radiology: Imaging Cancer; and Member of Board of Directors for the Society of Breast Imaging. LJE. Uncompensated board member for Quantum Leap Healthcare Collaborative, which provides funding to University of California San Francisco, for the I-SPY TRIAL; payment from UpToDate for editing medical materials; member of Blue Cross Blue Shield medical advisory panel and travel reimbursement from Blue Cross Blue Shield for attending medical advisory panel meeting.\u00a0NH. Member of RSNA Science Council. RAM. Research support and honoraria from GE Healthcare and NCI; institutional research funding from UCSF; and is an unpaid member of the Scientific Advisory Board for the Lobular Breast Cancer Alliance.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}